Evidence map›Paper›PMID 36699264›Full record

ArticleHeliyon2023

Circulating FK506 binding protein 51 mRNA expression in patients with pituitary adenomas.

Yingying Yang, Lilit Babayan, Argishty Mirzakhanian, Nvard Sisliyan, Dongyun Zhang, Carolina Hurtado, Abdul Zahid, Marvin Bergsneider, Won Kim, Marilene B Wang and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Heliyon, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Yingying YangDepartments of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.
Lilit BabayanDepartments of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.
Argishty MirzakhanianDepartments of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.
Nvard SisliyanDepartments of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.
Dongyun ZhangDepartments of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.
Carolina HurtadoDepartments of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.
Abdul ZahidDepartments of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.
Marvin BergsneiderDepartments of Neurosurgery, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.
Won KimDepartments of Neurosurgery, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.
Marilene B WangDepartments of Head and Neck Surgery, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.
Anthony P HeaneyDepartments of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.
University of California, Los Angeles · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: FK506 binding protein 51 (FKBP5) is a co-chaperone regulator of the glucocorticoid receptor (GR). Recent studies have reported increased FKBP5 mRNA in the circulation from patients with Cushing disease (CD) which returned to comparable levels seen in healthy controls following successful Methods: Pre-operative blood was collected from consecutive patients undergoing TNTS for pituitary tumors (n = 57) at our center between 2015 and 2019. Total RNA was isolated from whole blood using RiboPure blood RNA isolation kit and real-time qPCR was used to quantitate circulating FKBP5 mRNA expression. Results: Consistent with the prior report, higher circulating FKBP5 mRNA levels were observed in 20 patients with CD prior to surgical tumor removal, compared to 21 healthy controls (p < 0.0005) and compared to 8 patients harboring gonadotroph pituitary tumors (p < 0.05) and 6 patients with silent corticotroph pituitary tumors (p < 0.05). However, circulating FKBP5 mRNA levels were higher in 10 patients with prolactin (PRL)-secreting pituitary tumors compared to healthy controls (p < 0.05), and did not differ between patients with CD and patients with growth hormone secreting tumors (GH-omas). Conclusions: Although we confirm that circulating FKBP5 mRNA is higher in patients with corticotroph tumors compared to healthy subjects, measurement of circulating FKBP5 does not appear to be helpful to distinguish corticotroph tumors from other pituitary tumor sub-types.

Indexed as

Circulating biomarkerCushing disease (CD)FKBP5Pituitary tumors

Identifiers

PMID36699264
PMCPMC9868367
OpenAlexW4313593957

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.